Loading organizations...
§ Private Profile · Celixir House, Innovation Way, Stratford Business and Technology Park, Banbury Road, Stratford-upon-Avon, CV37 7GZ, England, United Kingdom
Regenerative medicine company that discovers and develops cell therapy and gene therapy treatments for heart disease, focused on using stem cells.
Key people at Celixir.
Celixir is a regenerative medicine company based in Stratford-Upon-Avon, United Kingdom, that discovers and develops advanced cell and gene therapies for clinical applications. The biotechnology firm focuses primarily on creating experimental treatments for complex cardiac conditions by utilizing specialized stem cell technologies to target heart disease. Operating within the broader life sciences sector, the organization conducts extensive preclinical research and experimental development to address severe cardiovascular ailments that lack adequate therapeutic options. Prior to operating under its current corporate structure, the enterprise was previously known through various legal entities, including Cardiogeni Limited, Celixir Innovations Limited, and Cell Therapy Limited. The organization maintains active corporate filings in the United Kingdom, with its most recent financial accounts made up to April 2024 and its next statement scheduled for May 2026. The current legal entity was officially incorporated in 2016.
Celixir Limited is a UK-registered private limited company (company number 10141208), headquartered at Celixir House, Innovation Way, Stratford-Upon-Avon, England, CV37 7GZ.[3][4] It appears tied to the biotech sector, notably as an investor or associated entity with Cardiogeni, a company focused on cardiovascular therapies, though specific details on its products, mission, or operations remain limited in public records.[4] No evidence confirms it as an investment firm or active portfolio company with detailed growth metrics; available data points to a low-profile entity without disclosed product offerings, customer base, or market traction.[3]
Celixir Limited was incorporated on April 22, 2016, as per UK Companies House records, but no public information details its founders, key personnel, or early milestones.[3] Its address links it to Cardiogeni, suggesting possible origins in biotech investment or support, potentially emerging amid UK life sciences growth post-2010s.[4] Lacking backstory on idea emergence or traction, it remains an opaque entity without noted pivotal moments.[3]
Public data on Celixir Limited is sparse, precluding a full assessment of unique strengths. Key observations:
Celixir operates—if at all prominently—in the UK biotech ecosystem, potentially riding trends in regenerative medicine via its Cardiogeni tie, where market forces like aging populations and post-Brexit life sciences funding (e.g., £1B+ government investments) favor innovation.[4] Timing aligns with 2016 incorporation amid global biotech booms, but without influence metrics, its ecosystem impact appears negligible; it neither shapes trends nor draws notable market tailwinds beyond basic registration.[3] This positions it as a minor, non-disruptive player amid dominant forces like AI-drug discovery and gene editing.
With minimal public footprint, Celixir's path hinges on undisclosed biotech involvement, potentially growing via Cardiogeni synergies if cardiovascular tech scales amid rising demand for heart therapies.[4] Trends like precision medicine and UK R&D incentives could propel it, evolving its role from obscurity to niche investor—yet persistent data gaps suggest limited near-term influence unless filings reveal momentum.[3] Its quiet profile underscores broader challenges for under-the-radar firms in competitive tech landscapes.
Key people at Celixir.
